79 related articles for article (PubMed ID: 23177617)
1. Papillary thyroid carcinoma with bone formation.
Na KY; Kim HS; Lee SK; Jung WW; Sung JY; Kim YW; Park YK
Pathol Res Pract; 2013 Jan; 209(1):14-8. PubMed ID: 23177617
[TBL] [Abstract][Full Text] [Related]
2. Expression of BMP-4 in papillary thyroid carcinoma and its correlation with tumor invasion and progression.
Meng X; Zhu P; Li N; Hu J; Wang S; Pang S; Wang J
Pathol Res Pract; 2017 Apr; 213(4):359-363. PubMed ID: 28214211
[TBL] [Abstract][Full Text] [Related]
3. Caveolin-1 expression in papillary thyroid carcinoma: correlation with clinicopathological parameters and BRAF mutation status.
Paskaš S; Janković J; Marečko I; Išić Denčić T; Tatić S; Cvejić D; Savin S
Otolaryngol Head Neck Surg; 2014 Feb; 150(2):201-9. PubMed ID: 24255086
[TBL] [Abstract][Full Text] [Related]
4. [Expression of microRNA-221 and IL-17 in papillary thyroid carcinoma and correlation with clinicopathologic features].
Jiang XL; Zhang H; Chen YL; Peng L
Zhonghua Bing Li Xue Za Zhi; 2017 Mar; 46(3):160-165. PubMed ID: 28297755
[No Abstract] [Full Text] [Related]
5. LDOC1 inhibits proliferation and promotes apoptosis by repressing NF-κB activation in papillary thyroid carcinoma.
Zhao S; Wang Q; Li Z; Ma X; Wu L; Ji H; Qin G
J Exp Clin Cancer Res; 2015 Dec; 34():146. PubMed ID: 26637328
[TBL] [Abstract][Full Text] [Related]
6. Receptor for activated protein C kinase 1 (RACK1) is overexpressed in papillary thyroid carcinoma.
Myklebust LM; Akslen LA; Varhaug JE; Lillehaug JR
Thyroid; 2011 Nov; 21(11):1217-25. PubMed ID: 22007921
[TBL] [Abstract][Full Text] [Related]
7. Expression of the membrane mucins MUC4 and MUC15, potential markers of malignancy and prognosis, in papillary thyroid carcinoma.
Nam KH; Noh TW; Chung SH; Lee SH; Lee MK; Hong SW; Chung WY; Lee EJ; Park CS
Thyroid; 2011 Jul; 21(7):745-50. PubMed ID: 21615302
[TBL] [Abstract][Full Text] [Related]
8. Strong immunoexpression of midkine is associated with multiple lymph node metastases in BRAFV600E papillary thyroid carcinoma.
Choi YW; Kim YH; Lee J; Soh EY; Park TJ; Kim JH
Hum Pathol; 2015 Oct; 46(10):1557-65. PubMed ID: 26297257
[TBL] [Abstract][Full Text] [Related]
9. [Detection of Runx2 mRNA expression using relatively real-time RT-PCR in papillary thyroid carcinoma].
Gong T; Wang J; Qian M; Zhou Y
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2013 Feb; 27(4):193-5. PubMed ID: 23631133
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of long non-coding RNA NR_036575.1 contributes to the proliferation and migration of papillary thyroid cancer.
Sun W; Lan X; Wang Z; Dong W; He L; Zhang T; Zhang H
Med Oncol; 2016 Sep; 33(9):102. PubMed ID: 27510368
[TBL] [Abstract][Full Text] [Related]
11. Increased type 3 deiodinase expression in papillary thyroid carcinoma.
Romitti M; Wajner SM; Zennig N; Goemann IM; Bueno AL; Meyer EL; Maia AL
Thyroid; 2012 Sep; 22(9):897-904. PubMed ID: 22823995
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of survivin expression and its prognostic value in papillary thyroid carcinoma.
Selemetjev S; Dencic TI; Marecko I; Jankovic J; Paunovic I; Savin S; Cvejic D
Pathol Res Pract; 2014 Jan; 210(1):30-4. PubMed ID: 24199968
[TBL] [Abstract][Full Text] [Related]
13. Gene expression in poorly differentiated papillary thyroid carcinomas.
Fluge Ø; Bruland O; Akslen LA; Lillehaug JR; Varhaug JE
Thyroid; 2006 Feb; 16(2):161-75. PubMed ID: 16676402
[TBL] [Abstract][Full Text] [Related]
14. Thymosin beta 10 correlates with lymph node metastases of papillary thyroid carcinoma.
Zhang XJ; Su YR; Liu D; Xu DB; Zeng MS; Chen WK
J Surg Res; 2014 Dec; 192(2):487-93. PubMed ID: 24974154
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic significance of elevated expression of HBME-1 in papillary thyroid carcinoma.
Chen YJ; Zhao RM; Zhao Q; Li BY; Ma QY; Li X; Chen X
Tumour Biol; 2016 Jul; 37(7):8715-20. PubMed ID: 26738867
[TBL] [Abstract][Full Text] [Related]
16. EWSR1 rearrangement is a frequent event in papillary thyroid carcinoma and in carcinoma of the thyroid with Ewing family tumor elements (CEFTE).
Oliveira G; Polónia A; Cameselle-Teijeiro JM; Leitão D; Sapia S; Sobrinho-Simões M; Eloy C
Virchows Arch; 2017 May; 470(5):517-525. PubMed ID: 28236059
[TBL] [Abstract][Full Text] [Related]
17. Suppressed Krüppel‑like factor 17 expression induces tumor proliferation, metastasis and a poor prognosis in papillary thyroid carcinoma.
Ye WC; Gao L; Huang J; Fang XM; Xie G
Mol Med Rep; 2014 Oct; 10(4):2087-92. PubMed ID: 25109837
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of cytokeratin 17 is associated with the development of papillary thyroid carcinoma and the presence of lymph node metastasis.
Kim HS; Lee JJ; Do SI; Kim K; Do IG; Kim DH; Chae SW; Sohn JH
Int J Clin Exp Pathol; 2015; 8(5):5695-701. PubMed ID: 26191283
[TBL] [Abstract][Full Text] [Related]
19. Up-regulation of urinary-type plasminogen activator correlates with high-risk papillary thyroid carcinoma with BRAF(V600E) mutation and its possible molecular mechanism.
Wakasa T; Li Y; Bai Y; Liu Z; Ozaki T; Mori I; Miyauchi A; Kakudo K; Nakamura M
Pathol Res Pract; 2014 Nov; 210(11):733-8. PubMed ID: 25085839
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical levels of cyclo-oxygenase-2, matrix metalloproteinase-9 and vascular endothelial growth factor in papillary thyroid carcinoma and their clinicopathological correlations.
Meng XY; Zhang Q; Li Q; Lin S; Li J
J Int Med Res; 2014 Jun; 42(3):619-27. PubMed ID: 24670538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
